Study seeks to measure how treatment affects development in devastating childhood disease

NCT ID NCT03862274

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Jessica Scherr Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how a rare, fatal childhood brain disease called CLN2 Batten disease affects children's development. Researchers will track 30 children, comparing those receiving a treatment called cerliponase alfa to those who are untreated. The goal is to measure changes in skills like language, movement, and problem-solving to better understand the disease and the treatment's effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BATTEN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States

Conditions

Explore the condition pages connected to this study.